ATTENUATED MYCOPLASMA GALLISEPTICUM STRAIN

摘要

PROBLEM TO BE SOLVED: To provide a live, attenuated Mycoplasma gallisepticum bacterium that exhibits reduced expression of a protein identified as MGA_0621.SOLUTION: In certain embodiments, the attenuated bacterium may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. A vaccine and a vaccination method involve the use of the live, attenuated M. gallisepticum bacterium, and a method for making the live, attenuated M. gallisepticum bacterium is also provided. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in a chicken.